AUTL
Price
$3.90
Change
-$0.07 (-1.76%)
Updated
Oct 3 closing price
27 days until earnings call
XBIO
Price
$4.53
Change
-$0.04 (-0.88%)
Updated
Oct 3 closing price
Ad is loading...

AUTL vs XBIO

Header iconAUTL vs XBIO Comparison
Open Charts AUTL vs XBIOBanner chart's image
Autolus Therapeutics
Price$3.90
Change-$0.07 (-1.76%)
Volume$680.85K
CapitalizationN/A
Xenetic Biosciences
Price$4.53
Change-$0.04 (-0.88%)
Volume$26.97K
CapitalizationN/A
View a ticker or compare two or three
AUTL vs XBIO Comparison Chart
Loading...
AUTL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
AUTL vs. XBIO commentary
Oct 04, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUTL is a StrongBuy and XBIO is a Buy.

COMPARISON
Comparison
Oct 04, 2024
Stock price -- (AUTL: $3.90 vs. XBIO: $4.53)
Brand notoriety: AUTL and XBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUTL: 94% vs. XBIO: 141%
Market capitalization -- AUTL: $965.92M vs. XBIO: $6.66M
AUTL [@Biotechnology] is valued at $965.92M. XBIO’s [@Biotechnology] market capitalization is $6.66M. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUTL’s FA Score shows that 0 FA rating(s) are green whileXBIO’s FA Score has 1 green FA rating(s).

  • AUTL’s FA Score: 0 green, 5 red.
  • XBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, both AUTL and XBIO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUTL’s TA Score shows that 6 TA indicator(s) are bullish.

  • AUTL’s TA Score: 6 bullish, 2 bearish.

Price Growth

AUTL (@Biotechnology) experienced а +12.07% price change this week, while XBIO (@Biotechnology) price change was +16.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.64%. For the same industry, the average monthly price growth was +0.29%, and the average quarterly price growth was -7.26%.

Reported Earning Dates

AUTL is expected to report earnings on Oct 31, 2024.

XBIO is expected to report earnings on Aug 11, 2023.

Industries' Descriptions

@Biotechnology (+0.64% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AUTL($966M) has a higher market cap than XBIO($6.66M). XBIO YTD gains are higher at: 31.301 vs. AUTL (-39.441). XBIO has higher annual earnings (EBITDA): -5.01M vs. AUTL (-162.54M). AUTL has more cash in the bank: 706M vs. XBIO (7.3M). XBIO has less debt than AUTL: XBIO (153K) vs AUTL (50M). AUTL has higher revenues than XBIO: AUTL (10.5M) vs XBIO (2.52M).
AUTLXBIOAUTL / XBIO
Capitalization966M6.66M14,500%
EBITDA-162.54M-5.01M3,246%
Gain YTD-39.44131.301-126%
P/E RatioN/AN/A-
Revenue10.5M2.52M417%
Total Cash706M7.3M9,673%
Total Debt50M153K32,680%
FUNDAMENTALS RATINGS
AUTL vs XBIO: Fundamental Ratings
AUTL
XBIO
OUTLOOK RATING
1..100
6485
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
20
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
4753
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XBIO's Valuation (20) in the Biotechnology industry is in the same range as AUTL (46). This means that XBIO’s stock grew similarly to AUTL’s over the last 12 months.

XBIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AUTL (100). This means that XBIO’s stock grew similarly to AUTL’s over the last 12 months.

XBIO's SMR Rating (96) in the Biotechnology industry is in the same range as AUTL (98). This means that XBIO’s stock grew similarly to AUTL’s over the last 12 months.

AUTL's Price Growth Rating (47) in the Biotechnology industry is in the same range as XBIO (53). This means that AUTL’s stock grew similarly to XBIO’s over the last 12 months.

AUTL's P/E Growth Rating (100) in the Biotechnology industry is in the same range as XBIO (100). This means that AUTL’s stock grew similarly to XBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AUTL
RSI
ODDS (%)
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 8 days ago
84%
Declines
ODDS (%)
Bearish Trend 12 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
86%
View a ticker or compare two or three
Ad is loading...
AUTL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ECEAX32.81N/A
N/A
Eaton Vance Tax-Managed Eq Aset Allc C
DESGX24.17-0.08
-0.33%
DWS ESG Core Equity Institutional
HBLAX15.16-0.07
-0.46%
Hartford Balanced Income A
AIVCX17.56-0.09
-0.51%
American Funds International Vntg C
AIAFX24.49-0.24
-0.97%
abrdn Global Infrastructure A

AUTL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUTL has been loosely correlated with ACLX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if AUTL jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUTL
1D Price
Change %
AUTL100%
-1.76%
ACLX - AUTL
43%
Loosely correlated
-0.04%
VCYT - AUTL
36%
Loosely correlated
-2.44%
ALLO - AUTL
36%
Loosely correlated
+3.16%
BBIO - AUTL
35%
Loosely correlated
+2.19%
CABA - AUTL
35%
Loosely correlated
-6.51%
More